Novo-Nordisk A/S Newsroom

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

BenzingaJul 1 23:18

Novo Nordisk Analyst Ratings

BenzingaJul 1 23:17

Novo Nordisk Analyst Ratings

BenzingaJun 26 00:42

BMO Capital Maintains Outperform on Novo Nordisk, Maintains $163 Price Target

BenzingaJun 26 00:42

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

BenzingaJun 18 01:26

Novo Nordisk Analyst Ratings

BenzingaJun 18 01:25

Novo Nordisk Analyst Ratings

BenzingaJun 10 20:45

Argus Research Maintains Buy on Novo Nordisk, Raises Price Target to $160

BenzingaJun 10 20:45

European pharmaceutical giant praised by Goldman Sachs: innovation is king, and three shares received a “buy” rating

Zhitong FinanceMay 30 19:12

Canto Fitzgerald: The Novo Nordisk (NVO.US) rating was reaffirmed and adjusted from an increase in holdings to an increase rating, with a target price of $160.00.

Zhitong FinanceApr 18 22:02

Novo Nordisk Analyst Ratings

BenzingaApr 18 22:00

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

BenzingaApr 18 22:00

Novo Nordisk (NVO.US) was first covered by the Bank of Montreal in Canada, giving it an superior market rating, with a target price of $163.00.

Zhitong FinanceApr 12 17:21

Novo Nordisk Analyst Ratings

BenzingaApr 12 17:15

Novo Nordisk Analyst Ratings

BenzingaApr 5 21:35

Novo Nordisk Analyst Ratings

BenzingaApr 1 20:40

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

BenzingaApr 1 20:40

Novo Nordisk Analyst Ratings

BenzingaMar 20 21:00

Novo Nordisk Analyst Ratings

BenzingaMar 9 01:40

Novo Nordisk Analyst Ratings

BenzingaFeb 21 01:42